Mindray resolves dispute with Beckman Coulter; Cincinnati hospital invests in MA Dx startup;

@FierceMedDev: Syneron fattens revenue with slim-down, North American focus. More | Follow @FierceMedDev

@MarkHFierce: The latest weekly edition of FierceDiagnostics is ready for viewing. Check it out, and spread the word. Issue | Follow @MarkHFierce

@MichaelGFierce: Brain tumors succumb to drugs delivered via bone scaffold. News | Follow @MichaelGFierce

> Mindray Medical ($MR) said it has reached a settlement with Beckman Coulter ($BEC), an OEM manufacturing customer, regarding a commercial dispute. Mindray will take a $15 million charge in the 2013 fourth quarter concerning the litigation. Item

> Becton Dickinson ($BDX) said it has joined the National Patient Safety Foundation Corporate Council to promote improvements in patient safety. Item

> Second Sight Medical Products said that Popular Science magazine named its Argus II Retinal Prosthesis System as "invention of the year." Item   

> Cincinnati Children's Hospital Medical Center invested $1 million in diagnostics startup Claritas Genomics in Cambridge, MA, a spinout of Boston Children's Hospital and Life Technologies ($LIFE). Story (sub. req.)

> A group of Harvard University undergraduate students designed a disposable, electronic chemotherapy patch. Story

Biotech News

@FierceBiotech: GeNO, uniQure look to leap through biotech IPO window in Q4 rush. More | Follow @FierceBiotech

@JohnCFierce: True, first wave of cancer vaccines has been a disappointment. Good reason for skepticism as well--but that's almost always the case. | Follow @JohnCFierce

@DamianFierce: Updated: Roche taps immatics in immunotherapy cancer R&D deal worth up to $1B. More | Follow @DamianFierce

@EmilyMFierce: Yale study: Left-handed people have higher rates of schizophrenia, other psychotic disorders. News | Follow @EmilyMFierce

> Troubled Transcept ditching 43% of staff with eye on getting bought. Article

> Merck KGaA adds $232M China R&D partnership to growing cancer drug collaboration. More

> Helpful regulators, blockbuster drug strategy deliver a crop of major breakthroughs. Item

Pharma News

@FiercePharma: Tuesday's top news: Breakthrough hep C meds aren't yet for sale, but critics already taking aim at prices. Story | Follow @FiercePharma

@EricPFierce: Actavis takes aim at North Carolina plant, 310 jobs, as it looks to cut costs. More | Follow @EricPFierce

@CarlyHFierce: CFR chief angles for meeting with Adcock Ingram after top investor nixes $1.3B deal. Story | Follow @CarlyHFierce

> 2013's story: Fewer drug approvals, better selling drugs. Article

> AstraZeneca wins, Merck and AbbVie lose with new statin-use guidelines. Story

> Is Endo on the verge of a Valeant-type acquisition binge? Article

> Sanofi tries label gambit to hold off Nasacort copies. More

Drug Delivery News

> MedImmune taps Unilife for wearable biologic injectable tech. Report

> DNA-delivering patch spurs bone growth. Story

> Study: Once-toxic peptide may deliver large molecules. Article

> Sustained-release glaucoma treatment nets $25M for Liquidia's Envisia. More

> Brain tumors succumb to drugs delivered via bone scaffold. Report

> Carbon nanotubes sneak drugs past gatekeeper proteins. Item

Diagnostics News

> Response Genetics sees disappointing Q3 as Dx revenue declines. Story

> VolitionRx, heartened by early data, shifts to multiple colorectal cancer Dx studies. Article

> Ex-Sequenom CEO seeks compensation in wake of scandal-related firing. More

> Oxford Immunotec's Dx milestones could supercharge IPO. Report

> Myriad gears up for melanoma test rollout. Story

> Myriad's signature BRCA test continues to generate lion's share of revenue. Item

Biomarkers News

> Study: Left-handed people have higher rates of schizophrenia, other psychotic disorders. Story

> J&J, nonprofits fund new research into links between Down syndrome, Alzheimer's. More

> Protein in damaged tissue could be biomarker for muscular dystrophy. Article

> Biomarker could predict preeclampsia in pregnant women. Report

> U.K. crew eyes biomarker as flag for atrial fibrillation complications. Story

> Researchers flag protein biomarker for aggressive oral cancer. Item

Suggested Articles

Sherlock Biosciences teamed up with Cepheid to help develop its CRISPR-based molecular diagnostic tech in oncology, infections and the coronavirus.

The spine surgery company ATEC has moved to acquire Paris-based EOS imaging, makers of FDA-cleared scanners and 3D orthopedic planning software.

Digital molecule designer Insilico Medicine has launched a new preclinical research program focused on treatments for brain cancer.